Pixium Vision SA (ALPIX.PA) Fundamental Analysis & Valuation

EPA:ALPIXFR001400JX97

Current stock price

0.3764 EUR
-0.04 (-10.17%)
Last:

This ALPIX.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALPIX.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALPIX has reported negative net income.
  • In the past year ALPIX has reported a negative cash flow from operations.
ALPIX.PA Yearly Net Income VS EBIT VS OCF VS FCFALPIX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

  • ALPIX has a worse Return On Assets (-154.03%) than 98.11% of its industry peers.
Industry RankSector Rank
ROA -154.03%
ROE N/A
ROIC N/A
ROA(3y)-65.25%
ROA(5y)-66.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALPIX.PA Yearly ROA, ROE, ROICALPIX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALPIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPIX.PA Yearly Profit, Operating, Gross MarginsALPIX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600 -800

0

2. ALPIX.PA Health Analysis

2.1 Basic Checks

  • ALPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALPIX has more shares outstanding than it did 1 year ago.
  • ALPIX has a worse debt/assets ratio than last year.
ALPIX.PA Yearly Shares OutstandingALPIX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ALPIX.PA Yearly Total Debt VS Total AssetsALPIX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

2.2 Solvency

  • ALPIX has an Altman-Z score of -8.48. This is a bad value and indicates that ALPIX is not financially healthy and even has some risk of bankruptcy.
  • ALPIX has a worse Altman-Z score (-8.48) than 92.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.48
ROIC/WACCN/A
WACC5.07%
ALPIX.PA Yearly LT Debt VS Equity VS FCFALPIX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

  • ALPIX has a Current Ratio of 0.74. This is a bad value and indicates that ALPIX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALPIX has a Current ratio of 0.74. This is amonst the worse of the industry: ALPIX underperforms 94.34% of its industry peers.
  • A Quick Ratio of 0.74 indicates that ALPIX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.74, ALPIX is doing worse than 71.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
ALPIX.PA Yearly Current Assets VS Current LiabilitesALPIX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

1

3. ALPIX.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.60% over the past year.
  • The Revenue has decreased by -4.23% in the past year.
  • The Revenue has been decreasing by -5.07% on average over the past years.
EPS 1Y (TTM)29.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)-4.23%
Revenue growth 3Y3.13%
Revenue growth 5Y-5.07%
Sales Q2Q%-13.46%

3.2 Future

  • ALPIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.50% yearly.
  • The Revenue is expected to decrease by -35.08% on average over the next years. This is quite bad
EPS Next Y55%
EPS Next 2Y24.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.17%
Revenue Next 2Y-35.08%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALPIX.PA Yearly Revenue VS EstimatesALPIX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ALPIX.PA Yearly EPS VS EstimatesALPIX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1

4. ALPIX.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALPIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALPIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPIX.PA Price Earnings VS Forward Price EarningsALPIX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPIX.PA Per share dataALPIX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALPIX's earnings are expected to grow with 24.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.5%
EPS Next 3YN/A

0

5. ALPIX.PA Dividend Analysis

5.1 Amount

  • No dividends for ALPIX!.
Industry RankSector Rank
Dividend Yield N/A

ALPIX.PA Fundamentals: All Metrics, Ratios and Statistics

Pixium Vision SA

EPA:ALPIX (1/30/2024, 7:00:00 PM)

0.3764

-0.04 (-10.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.53M
Revenue(TTM)1.81M
Net Income(TTM)-10.52M
Analysts86.67
Price Target45.9 (12094.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)37.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.85
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.99
EYN/A
EPS(NY)-4.63
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0.44
BVpS-1.52
TBVpS-1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.25%
ROA(5y)-66.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 3.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z -8.48
F-Score3
WACC5.07%
ROIC/WACCN/A
Cap/Depr(3y)13%
Cap/Depr(5y)9.22%
Cap/Sales(3y)3.48%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y55%
EPS Next 2Y24.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.23%
Revenue growth 3Y3.13%
Revenue growth 5Y-5.07%
Sales Q2Q%-13.46%
Revenue Next Year-5.17%
Revenue Next 2Y-35.08%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.82%
OCF growth 3YN/A
OCF growth 5YN/A

Pixium Vision SA / ALPIX.PA Fundamental Analysis FAQ

What is the fundamental rating for ALPIX stock?

ChartMill assigns a fundamental rating of 0 / 10 to ALPIX.PA.


What is the valuation status of Pixium Vision SA (ALPIX.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to Pixium Vision SA (ALPIX.PA). This can be considered as Overvalued.


Can you provide the profitability details for Pixium Vision SA?

Pixium Vision SA (ALPIX.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for Pixium Vision SA?

The Earnings per Share (EPS) of Pixium Vision SA (ALPIX.PA) is expected to grow by 55% in the next year.